Trial · NCT00494481

E3 Breast Cancer Taxotere Combination

NCT00494481, Phase 2, Completed, Genzyme, a Sanofi Company; results first posted 2011-05-24

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. E3 Breast Cancer Taxotere Combination. Trials, record NCT00494481. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00494481

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: E3 Breast Cancer Taxotere Combination
NCT number: NCT00494481
Status: Completed
Phases: Phase 2
Enrollment: 64 participants, actual
Lead sponsor: Genzyme, a Sanofi Company
Conditions: Advanced Breast Cancer
Interventions: Vandetanib (ZD6474), Docetaxel
First posted: 2007-06-29
Last updated: 2016-09-30
Other registries' IDs: eudract:2005-003592-20
Results first posted: 2011-05-24

Source ClinicalTrials.gov

Registered outcomes1

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Number of Patients With a Disease Progression Event	RECIST tumour assessments carried out at screening (within 3 weeks before the 1st dose) and then as per site clinical practice until objective progression. The only additional mandatory RECIST assessment is at the point of data cut-off	Number of patients with objective disease progression or death (by any cause in the absence of objective progression)

Source ClinicalTrials.gov

Outcomes1

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Number of Patients With a Disease Progression Event	RECIST tumour assessments carried out at screening (within 3 weeks before the 1st dose) and then as per site clinical practice until objective progression. The only additional mandatory RECIST assessment is at the point of data cut-off		Participants	NUMBER

Source ClinicalTrials.gov

Results by group2

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Spread	Units
Number of Patients With a Disease Progression Event	Vandetanib Plus Docetaxel		24		Participants
Number of Patients With a Disease Progression Event	Placebo Plus Docetaxel		18		Participants

Source ClinicalTrials.gov

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Vandetanib Plus Docetaxel	35
Overall Study	STARTED	Placebo Plus Docetaxel	29
Overall Study	COMPLETED	Vandetanib Plus Docetaxel	6
Overall Study	COMPLETED	Placebo Plus Docetaxel	5
Overall Study	NOT COMPLETED	Vandetanib Plus Docetaxel	29
Overall Study	NOT COMPLETED	Placebo Plus Docetaxel	24

Source ClinicalTrials.gov

Adverse events234

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk
other	Neutropenia	Blood and lymphatic system disorders	Vandetanib Plus Docetaxel	15	33
other	Neutropenia	Blood and lymphatic system disorders	Placebo Plus Docetaxel	13	29
other	Leukopenia	Blood and lymphatic system disorders	Vandetanib Plus Docetaxel	10	33
other	Leukopenia	Blood and lymphatic system disorders	Placebo Plus Docetaxel	8	29
other	Anaemia	Blood and lymphatic system disorders	Vandetanib Plus Docetaxel	6	33
other	Anaemia	Blood and lymphatic system disorders	Placebo Plus Docetaxel	6	29
other	Thrombocytopenia	Blood and lymphatic system disorders	Vandetanib Plus Docetaxel	4	33
other	Thrombocytopenia	Blood and lymphatic system disorders	Placebo Plus Docetaxel	0	29
other	Febrile Neutropenia	Blood and lymphatic system disorders	Vandetanib Plus Docetaxel	3	33
other	Febrile Neutropenia	Blood and lymphatic system disorders	Placebo Plus Docetaxel	0	29

1 to 10 of 234Source ClinicalTrials.gov

See all 234 adverse events

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Vandetanib Plus Docetaxel
Total, all-cause mortality	Placebo Plus Docetaxel
Total, other adverse events	Vandetanib Plus Docetaxel	33	33
Total, other adverse events	Placebo Plus Docetaxel	25	29
Total, serious adverse events	Vandetanib Plus Docetaxel	14	33
Total, serious adverse events	Placebo Plus Docetaxel	12	29

Source ClinicalTrials.gov

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons2

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison	Source
Vandetanib Plus Docetaxel vs Placebo Plus Docetaxel: Number of Patients With a Disease Progression Event	Trial comparisons
Vandetanib Plus Docetaxel vs Placebo Plus Docetaxel: serious adverse events	Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT00494481

GET https://conductscience.org/api/trials/v1/NCT00494481/events?page=2

API reference For AI assistants